Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
4.570
+0.180 (4.10%)
Aug 22, 2025, 4:00 PM - Market closed
Atai Life Sciences Stock Forecast
Stock Price Forecast
The 3 analysts that cover Atai Life Sciences stock have a consensus rating of "Strong Buy" and an average price target of $13.33, which forecasts a 191.68% increase in the stock price over the next year. The lowest target is $11 and the highest is $15.
Price Target: $13.33 (+191.68%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Atai Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $15 | Strong Buy | Maintains | $10 → $15 | +228.23% | Jul 30, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $14 | Buy | Initiates | $14 | +206.35% | Jul 29, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +140.70% | Jul 28, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 → $12 | Strong Buy | Maintains | $11 → $12 | +162.58% | Jul 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +118.82% | May 20, 2025 |
Financial Forecast
Revenue This Year
1.61M
from 308.00K
Increased by 423.05%
Revenue Next Year
218.58K
from 1.61M
Decreased by -86.43%
EPS This Year
-0.48
from -0.93
EPS Next Year
-0.51
from -0.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.3M | 1.6M | 230.3M | ||
| Avg | 1.6M | 218,576 | 57.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 956.8% | -2.2% | 105,250.2% | ||
| Avg | 423.1% | -86.4% | 26,079.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.36 | -0.28 | -0.34 | ||
| Avg | -0.48 | -0.51 | -0.44 | ||
| Low | -0.71 | -0.90 | -0.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.